| GO ID | GO name | Interaction type | Reference |
|---|---|---|---|
| GO:0005249 | Voltage-gated potassium channel activity | Decreases phenotype | PMID:36511510 |
| GO:0006007 | Glucose catabolic process | Increases phenotype | PMID:31704469 |
| GO:0006304 | Dna modification | Decreases phenotype | PMID:28659405 |
| GO:0006898 | Receptor-mediated endocytosis | Increases phenotype | PMID:29329451 |
| GO:0007173 | Epidermal growth factor receptor signaling pathway | Increases phenotype | PMID:29329451 |
| GO:0008283 | Cell population proliferation | Decreases phenotype | PMID:31704469 |
| GO:0019249 | Lactate biosynthetic process | Increases phenotype | PMID:31704469 |
| GO:0019835 | Cytolysis | Increases phenotype | PMID:31704469 |
| GO:0032148 | Activation of protein kinase b activity | Increases phenotype | PMID:35137321 |
| GO:0033148 | Positive regulation of intracellular estrogen receptor signaling pathway | Increases phenotype | PMID:26022396 |
| GO:0033993 | Response to lipid | Decreases phenotype | PMID:28659405 |
| GO:0035176 | Social behavior | Decreases phenotype | PMID:35137321 |
| GO:0040015 | Negative regulation of multicellular organism growth | Increases phenotype | PMID:35137321 |
| GO:0042554 | Superoxide anion generation | Affects phenotype | PMID:31923579 |
| GO:0042866 | Pyruvate biosynthetic process | Increases phenotype | PMID:31704469 |
| GO:0043433 | Negative regulation of dna-binding transcription factor activity | Increases phenotype | PMID:26022396 |
| GO:0044237 | Cellular metabolic process | Decreases phenotype | PMID:31704469; PMID:36511510 |
| GO:0045727 | Positive regulation of translation | Increases phenotype | PMID:35137321 |
| GO:0046323 | Glucose import | Affects phenotype | PMID:31923579 |
| GO:0050679 | Positive regulation of epithelial cell proliferation | Decreases phenotype | PMID:28659405 |
| GO:0050847 | Progesterone receptor signaling pathway | Decreases phenotype | PMID:26022396 |
| GO:0051602 | Response to electrical stimulus | Affects phenotype | PMID:35137321 |
| GO:0060075 | Regulation of resting membrane potential | Affects phenotype | PMID:36511510 |
| GO:0070374 | Positive regulation of erk1 and erk2 cascade | Increases phenotype | PMID:29329451 |
| GO:0072593 | Reactive oxygen species metabolic process | Affects phenotype | PMID:31923579 |
| GO:0090394 | Negative regulation of excitatory postsynaptic potential | Affects phenotype | PMID:35137321 |
| GO:0098781 | Ncrna transcription | Increases phenotype | PMID:28541575 |
| GO:0098900 | Regulation of action potential | Affects phenotype | PMID:36511510 |
| GO:0098990 | Ampa selective glutamate receptor signaling pathway | Affects phenotype | PMID:35137321 |
| GO:1900454 | Positive regulation of long-term synaptic depression | Affects phenotype | PMID:35137321 |
| GO:2001057 | Reactive nitrogen species metabolic process | Affects phenotype | PMID:31923579 |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.